封面
市場調查報告書
商品編碼
1672854

DNA 修復藥物市場按藥物類型、用途、給藥途徑、分銷管道和地區分類

DNA Repair Drugs Market, By Drug Type, By Application, By Route of Administration, By Distribution Channel, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025 年全球 DNA 修復藥物市場規模估計為 80.5 億美元,預計到 2032 年將達到 192.9 億美元,2025 年至 2032 年的年複合成長率(CAGR)為 13.3%。

報告範圍 報告詳細資訊
基準年 2024 2025 年市場規模 80.5億美元
效能資料 2020-2024 預測期 2025-2032
預測期:2025 年至 2032 年複合年成長率 13.30% 2032 年金額預測 192.9億美元
數字。 2025 年 DNA 修復藥物市場佔有率(按地區)
DNA 修復藥物市場-IMG1

DNA修復藥物旨在提高細胞識別和修復受損DNA的能力,可能用於治療癌症和其他與基因組不穩定性相關的疾病。人體內的 DNA 會因環境暴露和其他細胞過程而自然磨損,隨著時間的推移,會導致斷裂和其他類型的損傷。正常情況下,細胞會透過進化最佳化DNA修復途徑來修復此類損傷並防止突變的累積。然而,某些疾病狀態與 DNA 修復缺陷有關。藥理學增強 DNA 修復機制可能有助於解決未滿足的需求。一些生技公司和大型製藥公司正在研究針對修復途徑中的關鍵蛋白質(如PARP、ATR、ATM和其他參與DNA損害反應的分子)的DNA修復藥物。這一新興領域有望為開發癌症和遺傳疾病的精準療法帶來希望。

市場動態

全球 DNA 修復藥物市場的成長是由全球癌症發生率的上升以及 DNA 損傷與各種疾病發展之間的關聯在臨床上的重要性日益增加所推動的。此外,增加醫藥研發投入以確定 DNA 修復途徑中的分子標靶以及對各種候選藥物進行持續的臨床試驗,可能會為市場參與企業提供有利可圖的機會。然而,與 DNA 生物學相關的複雜性和與脫靶效應相關的安全風險可能會阻礙全面理解和臨床應用。過高的開發成本也可能成為市場發展的障礙。業界正專注於生物標記策略來選擇有反應的患者群體和聯合治療方法,以最大限度地提高療效同時最大限度地降低毒性。未來的藥物研發工作可能拓寬視野,不僅限於癌症。

研究的主要特點

  • 本報告對全球 DNA 修復藥物市場進行了詳細分析,並以 2024 年為基準年,給出了預測期(2025-2032 年)的市場規模(十億美元)和年複合成長率(CAGR%)。
  • 它揭示了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。
  • 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
  • 全球 DNA 修復藥物市場的主要企業根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行分析。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
  • 全球 DNA 修復藥物市場報告迎合了該行業的各個相關人員,例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
  • 相關人員可以透過全球 DNA 修復劑市場分析中使用的各種策略矩陣來促進他們的決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要
  • 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 影響分析
  • 市場趨勢
  • 監管情景
  • 收購和合作場景
  • 資金籌措和投資
  • PEST分析
  • 波特的分析

第4章全球DNA 修復藥物市場-冠狀病毒 (COVID-19) 大流行的影響

  • 整體影響
  • 政府舉措
  • COVID-19 市場影響

5. 2020-2032 年全球 DNA 修復藥物市場(按藥物類型分類)(十億美元)

  • 介紹
  • 尼拉帕尼(Zejula)
  • LYNPARZA( Lynparza )
  • Rucaparib(Rubraca)
  • 他拉唑帕尼(Talzenna)

6.全球DNA 修復藥物市場,按應用分類,2020-2032 年(十億美元)

  • 介紹
  • 卵巢癌
  • 乳癌
  • 攝護腺癌
  • 肺癌
  • 腹膜癌
  • 其他

7. 2020 年至 2032 年按給藥途徑分類的全球 DNA 修復藥物市場(十億美元)

  • 介紹
  • 口服
  • 腸外
  • 其他

8. 2020-2032 年全球 DNA 修復藥物市場按分銷管道分類(十億美元)

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

9. 2020 年至 2032 年全球 DNA 修復藥物市場(按地區分類)(十億美元)

  • 介紹
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第10章 競爭格局

  • 公司簡介
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Clovis Oncology
    • Johnson & Johnson Services, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline plc(GSK)
    • Novartis AG
    • Roche Holding AG
    • Agios Pharmaceuticals, Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • BioMarin Pharmaceutical Inc.
    • Takeda Pharmaceutical Company Limited
    • NMS Group

第 11 章 分析師建議

  • 興衰
  • 一致的機會地圖

第 12 章參考文獻與調查方法

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI2617

Global Dna Repair Drugs Market is estimated to be valued at USD 8.05 Bn in 2025 and is expected to reach USD 19.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 8.05 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 13.30% 2032 Value Projection: USD 19.29 Bn
Figure. Dna Repair Drugs Market Share (%), By Region 2025
DNA Repair Drugs Market - IMG1

DNA repair drugs aim to improve the ability of cells to identify and repair damaged DNA, which could have applications in treating cancer and other diseases related to genomic instability. DNA in the human body undergoes natural wear and tear from environmental exposures and other cellular processes that can cause breaks and other types of damage over time. Under normal circumstances, cells have evolutionarily optimized DNA repair pathways to fix such lesions and prevent mutations from accumulating. However, certain medical conditions are linked to deficiencies in DNA repair capacity. Enhancing DNA repair mechanisms pharmaceutically could help address unmet clinical needs. Several biotechs and big pharmaceutical firms are researching DNA repair drugs that target key proteins in repair pathways such as PARP, ATR, ATM and other molecules involved in DNA damage response. This budding field holds promise for developing precision medicines for cancer and genetic disorders.

Market Dynamics:

Global DNA repair drugs market growth is driven by rising cancer burden worldwide and growing clinical emphasis on DNA damage links to various disease pathogenesis. Furthermore, increasing pharmaceutical R&D investments to identify molecular targets in DNA repair pathways and ongoing clinical trials for various candidates can offer lucrative opportunities for market players. However, complexities associated with DNA biology and safety risks pertaining to off-target effects can hamper complete understanding and clinical translation. High costs of development can hamper the market growth. Industry players are focused on biomarker strategies to select responder patient populations and combination therapy approaches to maximize efficacy while minimizing toxicity. Future discovery efforts can expand the scope into non-oncology areas.

Key Features of the Study:

  • This report provides in-depth analysis of the global DNA repair drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global DNA repair drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Genentech, Pfizer, AstraZeneca
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

Detailed Segmentation-

  • By Drug Type
    • Niraparib (Zejula)
    • Olaparib (Lynparza)
    • Rucaparib (Rubraca)
    • Talazoparib (Talzenna)
  • By Route of Administration
    • Oral
    • Parenteral
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Clovis Oncology
    • Johnson & Johnson Services, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline plc (GSK)
    • Novartis AG
    • Roche Holding AG
    • Agios Pharmaceuticals, Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • BioMarin Pharmaceutical Inc.
    • Takeda Pharmaceutical Company Limited
    • NMS Group

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Application
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global DNA Repair Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global DNA Repair Drugs Market, By Drug Type, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Niraparib (Zejula)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Olaparib (Lynparza)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rucaparib (Rubraca)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Talazoparib (Talzenna)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global DNA Repair Drugs Market, By Application, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Ovarian Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Breast Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Prostate Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Lung Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Peritoneal Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global DNA Repair Drugs Market, By Route of Administration, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global DNA Repair Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global DNA Repair Drugs Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • AstraZeneca PLC
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Clovis Oncology
    • Johnson & Johnson Services, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline plc (GSK)
    • Novartis AG
    • Roche Holding AG
    • Agios Pharmaceuticals, Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • BioMarin Pharmaceutical Inc.
    • Takeda Pharmaceutical Company Limited
    • NMS Group

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact